Pharmaceutical industry: latest news

Pharmaceutical industry features

Pharmaceutical industry news from aidsmap

More news

Pharmaceutical industry news selected from other sources

  • US: How Insurers Are Finding Ways to Shift Costs to the Sick

    Health insurance companies are no longer allowed to turn away patients because of their pre-existing conditions or charge them more because of those conditions. But some health policy experts say insurers may be doing so in a more subtle way: by forcing people with a variety of illnesses — including Parkinson’s disease, diabetes and epilepsy — to pay more for their drugs.

    18 September 2014 | New York Times
  • Gilead’s Proposed Hepatitis C Medicines License: How Badly Will it Miss the Target?

    Gilead’s proposed license, and its limitations, is important because Gilead has applied for patents on Sovaldi® and ledipasvir in many countries, although a number of countries in the probable licensed territory are without patents. As a patent holder, Gilead generally has rights to exclude competitors and charge monopoly prices on these life-saving medicines. The anticipated license will set precise terms on which companies can make generic equivalents and where and under what circumstances those generics can be sold. In other words, Gilead sits in the driver’s seat and has enormous power to decide who does and doesn’t get more affordable access to generics of assured quality.

    17 September 2014 | Infojustice
  • Access to sofosbuvir in middle-income countries

    Gilead is excluding 51 middle income countries (MICs) from its license for sofosbuvir, an oral hepatitis C drug. Across these MICs, where nearly 50 million people are infected with hepatitis C virus (HCV), lack of access to generic sofosbuvir will increase the total cost of curing hepatitis C by an estimated $60 billion dollars, according to I-MAK’s analysis.

    17 September 2014 | I-MAK
  • Open Letter to President-elect Jean-Claude Juncker on move of medicinal products and health technologies to the portfolio of the Commissioner for internal market and industry

    We are writing to express our astonishment and concern regarding your decision to move the competence for medicinal products and health technologies from the Commissioner in charge of Health to the Commissioner in charge of internal market and industry within the new Commission.

    17 September 2014 | EATG
  • Gilead to raise price for new hepatitis C drug above $84000

    The fixed-dose regimen version of Gilead Sciences Inc's $84,000 hepatitis C drug, already under fire for its record-breaking costs, is going to be even more expensive.

    15 September 2014 | Reuters
  • New medicines in development give hope to patients with HIV/AIDS

    America’s biopharmaceutical research companies are currently developing 44 medicines and vaccines for HIV/AIDS treatment and prevention, according to the latest Medicines in Development report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

    11 September 2014 | Pharmaceutical Research and Manufacturers of America
  • Gilead close to sending $84,000 drug to poor countries

    Gilead Sciences Inc. is close to a pact with generic drugmakers to bring low-cost versions of its $84,000 hepatitis C drug Sovaldi to about 80 developing countries including India, Indonesia, and Pakistan.

    09 September 2014 | Bloomberg
  • New Tenofovir Alafenamide Combo Pill Has Less Effect on Kidneys and Bones

    An experimental single-tablet regimen containing a new version of tenofovir (tenofovir alafenamide or TAF) and the HIV protease inhibitor darunavir (Prezista) worked as well as a similar regimen containing the older tenofovir disoproxil fumarate (TDF) formulation,but it had less detrimental effects on kidney function and bone density, as study presented at the recent ICAAC conference heard.

    09 September 2014 | HIVandhepatitis.com
  • Poor patients in India facing HIV/AIDS drug shortages

    People with HIV in India are facing stoppages and shortfalls in their HIV treatment that have been blamed on supply bottlenecks, late payments to drugmakers and at least one large Indian manufacturer boycotting the process, complaining that the government was not paying it for its supply.

    05 September 2014 | Reuters
  • EU marketing authorization for ViiV Healthcare HIV drug Triumeq

    The European Commission has granted marketing authorization for ViiV Healthcare’s Triumeq(dolutegravir 50mg/abacavir 600mg/lamivudine 300mg) tablets for the treatment of HIV in adults and adolescents aged 12 years and older.

    04 September 2014 | Pharma Letter
More news


Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.